135 related articles for article (PubMed ID: 38262241)
1. Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy.
Dioun S; Chen L; De Meritens AB; St Clair CM; Hou JY; Khoury-Collado F; Pua T; Hershman DL; Wright JD
Gynecol Oncol; 2024 Mar; 182():70-74. PubMed ID: 38262241
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: A United States-based cost-effectiveness analysis.
Liu K; Zhu Y; Zhou Y; Zhang Y; Zhu H
Gynecol Oncol; 2022 Sep; 166(3):582-588. PubMed ID: 35781166
[TBL] [Abstract][Full Text] [Related]
3. Lenvatinib Plus Pembrolizumab vs. Chemotherapy in Pretreated Patients With Advanced Endometrial Cancer: A Cost-Effectiveness Analysis.
Feng M; Chen Y; Yang Y; Li Q
Front Public Health; 2022; 10():881034. PubMed ID: 35619813
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer in China.
Zheng Z; Yang L; Xu S; Zhu H; Cai H
Front Pharmacol; 2022; 13():944931. PubMed ID: 36249813
[No Abstract] [Full Text] [Related]
5. Dostarlimab for recurrent mismatch repair-deficient endometrial cancer: A cost-effectiveness study.
Dioun S; Chen L; Melamed A; Gockley A; St Clair CM; Hou JY; Khoury-Collado F; Hur C; Elkin E; Accordino M; Hershman DL; Wright JD
BJOG; 2023 Jan; 130(2):214-221. PubMed ID: 36330672
[TBL] [Abstract][Full Text] [Related]
6. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
Marth C; Tarnawski R; Tyulyandina A; Pignata S; Gilbert L; Kaen D; Rubio MJ; Frentzas S; Beiner M; Magallanes-Maciel M; Farrelly L; Choi CH; Berger R; Lee C; Vulsteke C; Hasegawa K; Braicu EI; Wu X; McKenzie J; Lee JJ; Makker V
Int J Gynecol Cancer; 2022 Jan; 32(1):93-100. PubMed ID: 34799418
[TBL] [Abstract][Full Text] [Related]
7. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
Makker V; Colombo N; Casado Herráez A; Santin AD; Colomba E; Miller DS; Fujiwara K; Pignata S; Baron-Hay S; Ray-Coquard I; Shapira-Frommer R; Ushijima K; Sakata J; Yonemori K; Kim YM; Guerra EM; Sanli UA; McCormack MM; Smith AD; Keefe S; Bird S; Dutta L; Orlowski RJ; Lorusso D;
N Engl J Med; 2022 Feb; 386(5):437-448. PubMed ID: 35045221
[TBL] [Abstract][Full Text] [Related]
8. Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer.
Yonemori K; Fujiwara K; Hasegawa K; Yunokawa M; Ushijima K; Suzuki S; Shikama A; Minobe S; Usami T; Kim JW; Kim BG; Wang PH; Chang TC; Yamamoto K; Han S; McKenzie J; Orlowski RJ; Miura T; Makker V; Man Kim Y
J Gynecol Oncol; 2024 Mar; 35(2):e40. PubMed ID: 38302725
[TBL] [Abstract][Full Text] [Related]
9. Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE-775.
Yonemori K; Yunokawa M; Ushijima K; Sakata J; Shikama A; Minobe S; Usami T; Enomoto T; Takehara K; Hasegawa K; Yamagami W; Yamamoto K; Han S; Dutta L; Orlowski R; Miura T; Makker V; Fujiwara K
Cancer Sci; 2022 Oct; 113(10):3489-3497. PubMed ID: 35612971
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer.
Thurgar E; Gouldson M; Matthijsse S; Amonkar M; Marinello P; Upadhyay N; Nwankwo C; Aguiar-Ibáñez R
J Med Econ; 2021; 24(1):675-688. PubMed ID: 33866938
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis.
Ackroyd SA; Huang ES; Kurnit KC; Lee NK
Gynecol Oncol; 2021 Aug; 162(2):249-255. PubMed ID: 34103196
[TBL] [Abstract][Full Text] [Related]
12. Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.
Barrington DA; Haight PJ; Calhoun C; Tubbs C; Cohn DE; Bixel KL
Gynecol Oncol; 2021 Sep; 162(3):626-630. PubMed ID: 34148720
[TBL] [Abstract][Full Text] [Related]
13. Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775.
Makker V; Colombo N; Casado Herráez A; Monk BJ; Mackay H; Santin AD; Miller DS; Moore RG; Baron-Hay S; Ray-Coquard I; Ushijima K; Yonemori K; Kim YM; Guerra Alia EM; Sanli UA; Bird S; Orlowski R; McKenzie J; Okpara C; Barresi G; Lorusso D
J Clin Oncol; 2023 Jun; 41(16):2904-2910. PubMed ID: 37058687
[No Abstract] [Full Text] [Related]
14. First-Line Lenvatinib Plus Pembrolizumab or Everolimus versus Sunitinib for Advanced Renal Cell Carcinoma: A United States-Based Cost-Effectiveness Analysis.
Zhu Y; Liu K; Ding D; Peng L
Clin Genitourin Cancer; 2023 Jun; 21(3):417.e1-417.e10. PubMed ID: 36529626
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Lenvatinib Plus Pembrolizumab or Everolimus as First-Line Treatment of Advanced Renal Cell Carcinoma.
Wang Y; Wang H; Yi M; Han Z; Li L
Front Oncol; 2022; 12():853901. PubMed ID: 35800045
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors with chemotherapy for primary advanced mismatch repair-deficient endometrial cancer: A cost-effectiveness analysis.
Kim J; Lim J; Lee SW; Park JY; Suh DS; Kim JH; Kim YM; Kim DY
Gynecol Oncol; 2023 Dec; 179():106-114. PubMed ID: 37976756
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer.
Wu M; Qin S; Wang L; Tan C; Peng Y; Zeng X; Luo X; Yi L; Wan X
Front Pharmacol; 2022; 13():881787. PubMed ID: 35712723
[No Abstract] [Full Text] [Related]
18. Pembrolizumab plus lenvatinib combination therapy for advanced endometrial carcinoma.
Walker CA; Spirtos AN; Miller DS
Expert Rev Anticancer Ther; 2023 Apr; 23(4):361-368. PubMed ID: 36944439
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
[TBL] [Abstract][Full Text] [Related]
20. Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas.
Okuma Y; Nomura S; Sakakibara-Konishi J; Tsukita Y; Murakami S; Hosomi Y; Tambo Y; Kogure Y; Yoshioka H; Tamiya M; Ninomiya K; Iwama E
Clin Lung Cancer; 2024 Jun; 25(4):389-394. PubMed ID: 38413246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]